Fesoterodin
Fesoterodin
Klass: A
Visa all info
Skriv ut
Kontakta oss
Produkter
Visa alla produkter
Fesoterodine 2care4, Fesoterodine Accord, Fesoterodine ......
Fesoterodine 2care4, Fesoterodine Accord, Fesoterodine Medical Valley, Fesoterodine STADA, TOVIAZATC-koder
G04BD11
G04BD11Substanser
fesoterodin, fesoterodinfumarat
fesoterodin, fesoterodinfumaratSammanfattning
Data från kliniska studier ger varierande resultat gällande könsskillnader. Eftersom genes och symptombild för urininkontinens och överaktiv blåsa delvis skiljer sig åt mellan kvinnor och män är könsskillnader i effekt av fesoterodin svårtolkade. De flesta studier har inkluderat få män och vilket ytterligare försvårar bedömning av eventuella könsskillnader.
Persistens vid antikolinergikabehandling är låg hos både kvinnor och män.
Background
Anticholinergic drugs reduce the bladder detrusor muscle contractions and are used to treat urgency incontinence and symptoms of overactive bladder. Due to sex differences in etiology of these symptoms, drug therapy differs as urinary retention must be ruled out before starting treatment with anticholinergic drugs. In women, anticholinergic drugs are commonly used when non-pharmacological treatments such as bladder training are insufficient [1]. In men, benign prostate hyperplasia is a common cause of urgency symptoms. Non-anticholinergic drugs, primarily alpha-1 blockers, are therefore often used as first-line treatment in men even though anticholinergic drugs are used in addition or as monotherapy [2-5]. Visa hela bakgrundstexten
The baseline symptoms described in studies differ between men and women regarding prevalence of incontinence episodes and frequency of urgency episodes [6, 7]. Treatment effects on these parameters are common outcomes in clinical studies and differences in treatment effect between men and women need to be interpreted in relation to differences at baseline. The placebo effec......
Försäljning på recept
Visa hela försäljning på recept
Fler kvinnor än män hämtade ut tabletter innehållande fesoterodin (ATC-kod G04BD11) på recept i Sverige år 2021, totalt 3 052 kvinnor och 2 147 män. Det motsvarar 0,6 respektive 0,4 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 70 år och äldre hos båda könen. I genomsnitt var tabletter innehållande fesoterodin 1,7 gånger vanligare hos kvinnor [28].
Referenser
Visa referenser
EAU Guidelines. Non-neurogenic Female LUTS. Uroweb [www]. [cited 2022-04-14].
Kaplan SA, Roehrborn CG, Abrams P, Chapple CR, Bavendam T, Guan Z. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract. 2011;65:487-507.
Giannitsas K, Athanasopoulos A. Male overactive bladder: pharmacotherapy for the male. Curr Opin Urol. 2013;23:515-9.
Andersson KE. The use of pharmacotherapy for male patients with urgency and stress incontinence. Curr Opin Urol. 2014;24:571-7.
EAU Guidelines. Management of Non-neurogenic Male LUTS. Uroweb [www]. [cited 2022-04-14].
Coyne KS, Sexton CC, Thompson CL, Milsom I, Irwin D, Kopp ZS et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009;104:352-60.
Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306-14; discussion 1314-5.
Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006;18:CD003781.
Lee S, Malhotra B, Creanga D, Carlsson M, Glue P. A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. BMC Med Res Methodol. 2009;9:55.
Mangera A, Chapple CR, Kopp ZS, Plested M. The placebo effect in overactive bladder syndrome. Nat Rev Urol. 2011;8:495-503.
Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - TOVIAZ (fesoterodine)
Malhotra BK, Wood N, Sachse R. Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. Int J Clin Pharmacol Ther. 2009;47:570-8.
Oishi M, Tomono Y, Yamagami H, Malhotra B. Population pharmacokinetics of the 5-hydroxymethyl metabolite of tolterodine after administration of fesoterodine sustained release tablet in Western and East Asian populations. J Clin Pharmacol. 2014;54:928-36.
Toviaz (fesoterodine). EPAR - Product information. European Medicines Agency (EMA) [updated 2021-10-26, cited 2022-07-06]
Scarpero H, Sand PK, Kelleher CJ, Berriman S, Bavendam T, Carlsson M. Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms. Curr Med Res Opin. 2011;27:921-30.
Kelleher CJ, Dmochowski RR, Berriman S, Kopp ZS, Carlsson M. Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies. BJU Int. 2012;110:392-400.
Ginsberg D, Schneider T, Kelleher C, Van Kerrebroeck P, Swift S, Creanga D et al. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder. BJU Int. 2013;112:373-85.
Herschorn S, Kaplan SA, Sun F, Ntanios F. Do patient characteristics predict responsiveness to treatment of overactive bladder with antimuscarinic agents?. Urology. 2014;83:1023-9.
Welk B, McArthur E. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study. BJU Int. 2020;126(1):183-190.
Akino H, Namiki M, Suzuki K, Fuse H, Kitagawa Y, Miyazawa K et al. Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study. Int J Urol. 2014;21:389-94.
Johnell K, Weitoft GR, Fastbom J. Sex differences in inappropriate drug use: a register-based study of over 600,000 older people. Ann Pharmacother. 2009;43:1233-8.
Kalder M, Pantazis K, Dinas K, Albert US, Heilmaier C, Kostev K. Discontinuation of treatment using anticholinergic medications in patients with urinary incontinence. Obstet Gynecol. 2014;124:794-800.
Krhut J, Gärtner M, Petzel M, Sykora R, Nemec D, Tvrdik J et al. Persistence with first line anticholinergic medication in treatment-naïve overactive bladder patients. Scand J Urol. 2014;48:79-83.
Cardozo L, Hall T, Ryan J, Ebel Bitoun C, Kausar I, Darekar A et al. Safety and efficacy of flexible-dose fesoterodine in British subjects with overactive bladder: insights into factors associated with dose escalation. Int Urogynecol J. 2012;23:1581-90.
Wagg A, Darekar A, Arumi D, Khullar V, Oelke M. Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people >65 years of age: A post hoc analysis of data from the SOFIA study. Neurourol Urodyn. 2015;34:438-43.
Lua LL, Pathak P, Dandolu V. Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents. Neurourol Urodyn. 2017;36(8):2123-2131.
Goodson AB, Cantrell MA, Shaw RF, Lund BC. Comparative Effectiveness of Anticholinergic Agents for Lower Urinary Tract Symptoms. J Manag Care Spec Pharm. 2018;24(1):65-72.
Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2021 [cited 2022-03-15.]
- EAU Guidelines. Non-neurogenic Female LUTS. Uroweb [www]. [cited 2022-04-14].
- Kaplan SA, Roehrborn CG, Abrams P, Chapple CR, Bavendam T, Guan Z. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract. 2011;65:487-507.
- Giannitsas K, Athanasopoulos A. Male overactive bladder: pharmacotherapy for the male. Curr Opin Urol. 2013;23:515-9.
- Andersson KE. The use of pharmacotherapy for male patients with urgency and stress incontinence. Curr Opin Urol. 2014;24:571-7.
- EAU Guidelines. Management of Non-neurogenic Male LUTS. Uroweb [www]. [cited 2022-04-14].
- Coyne KS, Sexton CC, Thompson CL, Milsom I, Irwin D, Kopp ZS et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009;104:352-60.
- Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50:1306-14; discussion 1314-5.
- Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2006;18:CD003781.
- Lee S, Malhotra B, Creanga D, Carlsson M, Glue P. A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. BMC Med Res Methodol. 2009;9:55.
- Mangera A, Chapple CR, Kopp ZS, Plested M. The placebo effect in overactive bladder syndrome. Nat Rev Urol. 2011;8:495-503.
- Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - TOVIAZ (fesoterodine)
- Malhotra BK, Wood N, Sachse R. Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. Int J Clin Pharmacol Ther. 2009;47:570-8.
- Oishi M, Tomono Y, Yamagami H, Malhotra B. Population pharmacokinetics of the 5-hydroxymethyl metabolite of tolterodine after administration of fesoterodine sustained release tablet in Western and East Asian populations. J Clin Pharmacol. 2014;54:928-36.
- Toviaz (fesoterodine). EPAR - Product information. European Medicines Agency (EMA) [updated 2021-10-26, cited 2022-07-06]
- Scarpero H, Sand PK, Kelleher CJ, Berriman S, Bavendam T, Carlsson M. Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms. Curr Med Res Opin. 2011;27:921-30.
- Kelleher CJ, Dmochowski RR, Berriman S, Kopp ZS, Carlsson M. Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies. BJU Int. 2012;110:392-400.
- Ginsberg D, Schneider T, Kelleher C, Van Kerrebroeck P, Swift S, Creanga D et al. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder. BJU Int. 2013;112:373-85.
- Herschorn S, Kaplan SA, Sun F, Ntanios F. Do patient characteristics predict responsiveness to treatment of overactive bladder with antimuscarinic agents?. Urology. 2014;83:1023-9.
- Welk B, McArthur E. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study. BJU Int. 2020;126(1):183-190.
- Akino H, Namiki M, Suzuki K, Fuse H, Kitagawa Y, Miyazawa K et al. Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study. Int J Urol. 2014;21:389-94.
- Johnell K, Weitoft GR, Fastbom J. Sex differences in inappropriate drug use: a register-based study of over 600,000 older people. Ann Pharmacother. 2009;43:1233-8.
- Kalder M, Pantazis K, Dinas K, Albert US, Heilmaier C, Kostev K. Discontinuation of treatment using anticholinergic medications in patients with urinary incontinence. Obstet Gynecol. 2014;124:794-800.
- Krhut J, Gärtner M, Petzel M, Sykora R, Nemec D, Tvrdik J et al. Persistence with first line anticholinergic medication in treatment-naïve overactive bladder patients. Scand J Urol. 2014;48:79-83.
- Cardozo L, Hall T, Ryan J, Ebel Bitoun C, Kausar I, Darekar A et al. Safety and efficacy of flexible-dose fesoterodine in British subjects with overactive bladder: insights into factors associated with dose escalation. Int Urogynecol J. 2012;23:1581-90.
- Wagg A, Darekar A, Arumi D, Khullar V, Oelke M. Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people >65 years of age: A post hoc analysis of data from the SOFIA study. Neurourol Urodyn. 2015;34:438-43.
- Lua LL, Pathak P, Dandolu V. Comparing anticholinergic persistence and adherence profiles in overactive bladder patients based on gender, obesity, and major anticholinergic agents. Neurourol Urodyn. 2017;36(8):2123-2131.
- Goodson AB, Cantrell MA, Shaw RF, Lund BC. Comparative Effectiveness of Anticholinergic Agents for Lower Urinary Tract Symptoms. J Manag Care Spec Pharm. 2018;24(1):65-72.
- Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2021 [cited 2022-03-15.]
Uppdaterat
Litteratursökningsdatum 3/12/2015
Litteratursökningsdatum 3/12/2015